首页> Journal for immunotherapy of cancer> SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.

SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137.

导出 LinkOut

翻译打印收藏纠错

第一作者： Takayuki,Kamikawa

第一单位： Chugai Pharmaceutical Co Ltd, Yokohama, Kanagawa, Japan.

作者： Takayuki,Kamikawa ^[1] ; Naoki,Kimura ^[2] ; Shinya,Ishii ^[1] ; Masaru,Muraoka ^[1] ; Tatsushi,Kodama ^[3] ; Kenji,Taniguchi ^[1] ; Moe,Yoshimoto ^[1] ; Momoko,Miura-Okuda ^[4] ; Ryo,Uchikawa ^[1] ; Chie,Kato ^[1] ; Junko,Shinozuka ^[1] ; Sho,Akai ^[1] ; Sotaro,Naoi ^[5] ; Nanami,Tomioka ^[1] ; Nishiki,Nagaya ^[5] ; Chai Ling,Pang ^[5] ; Gupta,Garvita ^[5] ; Shu,Feng ^[5] ; Mei,Shimada ^[1] ; Mika,Kamata-Sakurai ^[1] ; Hiroyuki,Aburatani ^[6] ; Takehisa,Kitazawa ^[1] ; Tomoyuki,Igawa ^[1]

作者单位： Chugai Pharmaceutical Co Ltd, Yokohama, Kanagawa, Japan. ^[1] Chugai Pharmaceutical Co Ltd, Yokohama, Kanagawa, Japan kimuranok@chugai-pharm.co.jp. ^[2] Chugai Pharmaceutical Co Ltd, Chuo-ku, Tokyo, Japan. ^[3] Chugai Pharmaceutical Co Ltd, Kita-ku, Tokyo, Japan. ^[4] Chugai Pharmabody Research Pte Ltd, Singapore. ^[5] The University of Tokyo, Bunkyo-ku, Japan. ^[6]

关键词 Bispecific T cell engager - BiTE Co-stimulatory molecules Immunotherapy Ovarian cancer T cell